CoChat

Neuropeptide pituitary adenylate cyclase‐activating polypeptide (PACAP) slows down Alzheimer's disease‐like pathology in amyloid precursor protein‐transgenic mice

Open access
Rat, Dorothea, Schmitt, Ulrich, Tippmann, Frank, Dewachter, Ilse, Theunis, Clara, Wieczerzak, Ewa, Postina, Rolf, van Leuven, Fred, Fahrenholz, Falk, Kojro, Elzbieta · 2011 · The FASEB Journal
Cited by 148

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Pituitary adenylate cyclase‐activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent α‐secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long‐term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain‐derived neurotrophic factor and of the antiapoptotic Bcl‐2 protein. In addition, it caused a strong reduction of the amyloid β‐peptide (Aβ) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin‐neprilysin cascade, also enhanced expression of the Aβ‐degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1‐receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long‐term PACAP treatment of APP[V717I]‐transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.—Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase‐activating polypeptide (PACAP) slows down Alzheimer's disease‐like pathology in amyloid precursor protein‐transgenic mice. FASEB J. 25, 3208‐3218 (2011). www.fasebj.org

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.10-180133

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 148

Metadata

Authors
Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E., Postina, R., van Leuven, F., Fahrenholz, F., & Kojro, E.
Venue
The FASEB Journal
Publisher
Wiley
Published
2011-01
Volume
25
Issue
9
Pages
3208-3218
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2098511020
Cited by
148
References
14
FWCI
6.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuropeptide pituitary adenylate cyclase‐activating polypeptide (PACAP) slows down Alzheimer's disease‐like pathology in amyloid precursor protein‐transgenic mice. https://app.cochat.ai/papers/10.1096/fj.10-180133
The paper
Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E., Postina, R., van Leuven, F., Fahrenholz, F., & Kojro, E. (2011). Neuropeptide pituitary adenylate cyclase‐activating polypeptide (PACAP) slows down Alzheimer's disease‐like pathology in amyloid precursor protein‐transgenic mice. The FASEB Journal. https://doi.org/10.1096/fj.10-180133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.